Product Description
Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)
Mechanisms of Action: Mitosis Inhibitor, Tubulin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Premier Inc
Company Location:
Company Founding Year: None
Additional Commercial Interests: Pfizer
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 27
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Lymphoid Leukemia|Diffuse Large B-Cell Lymphoma|Hodgkin Lymphoma|Lymphoma|Lymphoma, B-Cell|Other|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Retinoblastoma|Sarcoma, Ewing|T-Cell Peripheral Lymphoma
Phase 2: Burkitt Lymphoma|COVID-19|Desmoplastic Small Round Cell Tumor|Fetal Diseases|Follicular Lymphoma|Lymphoproliferative Disorders|Osteosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes|Primitive Neuroectodermal Tumors|Rhabdomyosarcoma|Small Cell Sarcoma|T-Cell Leukemia
Phase 1: Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03467373 |
NP40126 | P1 |
Completed |
Lymphoma, B-Cell|Lymphoma, Non-Hodgkin |
2024-12-02 |
41% |
2025-01-18 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05848765 |
REFRACT | P2 |
Recruiting |
Follicular Lymphoma |
2029-05-31 |
78% |
2024-11-27 |
|
NCT06709495 |
NCT06709495 | P2 |
Recruiting |
Sarcoma, Ewing|Osteosarcoma|Primitive Neuroectodermal Tumors|Small Cell Sarcoma|Desmoplastic Small Round Cell Tumor|Rhabdomyosarcoma|Peripheral Neuroectodermal Tumors, Primitive |
2028-11-01 |
12% |
2025-02-14 |
|
NCT06738368 |
RG1124788 | P2 |
Recruiting |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|Burkitt Lymphoma|Acute Lymphoid Leukemia |
2028-01-31 |
12% |
2026-01-31 |
|
NCT06954805 |
AAAV2404 | P2 |
Recruiting |
Lymphoma, B-Cell|Lymphoproliferative Disorders |
2027-04-14 |
2025-05-03 |
Primary Endpoints|Treatments |
|
NCT04980222 |
GO43075 | P2 |
Active, not recruiting |
Lymphoma |
2026-09-30 |
12% |
2025-11-19 |
Primary Completion Date|Primary Endpoints|Treatments |
NCT05280626 |
CIBI308Y047 | P2 |
Not yet recruiting |
Diffuse Large B-Cell Lymphoma |
2025-12-31 |
54% |
2024-11-27 |
Primary Endpoints|Treatments |
ACTRN12622000173796p |
SBSDS | P2 |
Not yet recruiting |
Pregnancy Outcomes|Fetal Diseases|Pregnancy Complications, Infectious|COVID-19 |
2022-12-31 |
|||
NCT04681417 |
RETINO2018 | P3 |
Recruiting |
Retinoblastoma |
2035-01-20 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT06072131 |
CRESCENDO | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2030-07-01 |
18% |
2024-11-27 |
|
2018-003335-29 |
2018-003335-29 | P3 |
Active, not recruiting |
Other |
2029-10-15 |
2022-03-13 |
Treatments |
|
NCT03117751 |
TOT17 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-09-30 |
10% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT02684708 |
EuroNet-PHL-C2 | P3 |
Active, not recruiting |
Hodgkin Lymphoma |
2026-09-30 |
2021-05-14 |
Primary Endpoints|Treatments|Trial Status |
|
2012-000793-30 |
IntReALL SR 2010 | P3 |
Completed |
Acute Lymphoid Leukemia |
2024-04-25 |
2025-05-06 |
Treatments |
|
NCT01478542 |
OPTIMAL>60 | P3 |
Completed |
Lymphoma, B-Cell |
2024-01-18 |
74% |
2024-04-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04231448 |
DEB | P3 |
Active, not recruiting |
Diffuse Large B-Cell Lymphoma |
2023-01-10 |
37% |
2024-12-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
CTR20192684 |
CTR20192684 | P3 |
Completed |
Diffuse Large B-Cell Lymphoma |
2025-06-29 |
2025-11-02 |
||
NCT04307576 |
ALLTogether1 | P3 |
Recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2033-06-01 |
59% |
2025-08-29 |
|
NCT06947967 |
SWIFT 02 | P3 |
Recruiting |
T-Cell Peripheral Lymphoma |
2032-12-01 |
33% |
2025-09-16 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status |
2019-004153-93 |
2019-004153-93 | P3 |
Active, not recruiting |
Sarcoma, Ewing |
2030-12-17 |
2025-06-19 |
Treatments |
|
NCT06533748 |
SJALL23H | P2 |
Recruiting |
Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2028-05-01 |
12% |
2025-01-11 |
|
NCT03755804 |
cHOD17 | P2 |
Active, not recruiting |
Hodgkin Lymphoma |
2027-01-01 |
12% |
2025-09-23 |
|
NCT02866136 |
RETINO2011 | P2 |
Active, not recruiting |
Retinoblastoma |
2023-01-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT06356129 |
GOLSEEK-1 | P3 |
Active, not recruiting |
Lymphoma, B-Cell |
2028-08-14 |
27% |
2026-02-13 |
Primary Endpoints|Trial Status |
NCT03020030 |
NCT03020030 | P3 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2026-11-30 |
40% |
2025-01-04 |